NO308307B1 - Forbindelse, farmasøytisk preparat omfattende denne samt anvendelse derav - Google Patents

Forbindelse, farmasøytisk preparat omfattende denne samt anvendelse derav

Info

Publication number
NO308307B1
NO308307B1 NO963355A NO963355A NO308307B1 NO 308307 B1 NO308307 B1 NO 308307B1 NO 963355 A NO963355 A NO 963355A NO 963355 A NO963355 A NO 963355A NO 308307 B1 NO308307 B1 NO 308307B1
Authority
NO
Norway
Prior art keywords
compound
pharmaceutical composition
pnd
pms
seizures
Prior art date
Application number
NO963355A
Other languages
English (en)
Norwegian (no)
Other versions
NO963355D0 (no
NO963355L (no
Inventor
Ravindra B Upasani
Haiji Xia
Derk Hogenkamp
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308307(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of NO963355D0 publication Critical patent/NO963355D0/no
Publication of NO963355L publication Critical patent/NO963355L/no
Publication of NO308307B1 publication Critical patent/NO308307B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
NO963355A 1994-02-14 1996-08-12 Forbindelse, farmasøytisk preparat omfattende denne samt anvendelse derav NO308307B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19691994A 1994-02-14 1994-02-14
US34692794A 1994-11-23 1994-11-23
PCT/US1995/001712 WO1995021617A1 (en) 1994-02-14 1995-02-14 Androstanes and pregnanes for allosteric modulation of gaba receptor

Publications (3)

Publication Number Publication Date
NO963355D0 NO963355D0 (no) 1996-08-12
NO963355L NO963355L (no) 1996-10-11
NO308307B1 true NO308307B1 (no) 2000-08-28

Family

ID=26892391

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963355A NO308307B1 (no) 1994-02-14 1996-08-12 Forbindelse, farmasøytisk preparat omfattende denne samt anvendelse derav

Country Status (18)

Country Link
EP (2) EP1038880B1 (de)
JP (1) JP4066272B2 (de)
KR (1) KR100338287B1 (de)
AT (2) ATE195654T1 (de)
AU (1) AU691905B2 (de)
BR (1) BR9506779A (de)
CA (1) CA2183231A1 (de)
DE (2) DE69518509T2 (de)
DK (2) DK1038880T3 (de)
ES (2) ES2151593T3 (de)
FI (2) FI118008B (de)
GR (1) GR3034810T3 (de)
HK (1) HK1014665A1 (de)
IL (1) IL112638A (de)
NO (1) NO308307B1 (de)
NZ (1) NZ282939A (de)
PT (2) PT752860E (de)
WO (1) WO1995021617A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9901138A3 (en) * 1995-06-06 1999-11-29 Cocensys Inc Irvine Neuroactive steroids of the androstane and pregnane series
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
AU780989B2 (en) * 1999-04-29 2005-04-28 Euro-Celtique S.A. 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
EP1449846A1 (de) * 1999-04-29 2004-08-25 Euro-Celtique S.A. 3alpha-hydroxy-3beta Methoxymethyl-21-heterozyklish substituierte Steroide mit anesthetische Aktivität
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
EP2322182A1 (de) 1999-09-30 2011-05-18 Harbor BioSciences, Inc. Androstenolderivate als Androgenrezeptormodulator
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
WO2001045674A1 (en) 1999-12-20 2001-06-28 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034796A2 (en) * 2006-09-19 2008-03-27 Solvay Pharmaceuticals Gmbh Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8580983B2 (en) 2006-11-21 2013-11-12 Umecrine Ab Steroids having increased water solubility and resistance against metabolism, and methods for their production
JP5663303B2 (ja) * 2007-06-15 2015-02-04 リサーチ トライアングル インスティテュート Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ302050B6 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
WO2013056181A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN104736158A (zh) 2012-01-23 2015-06-24 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
CN102702126B (zh) * 2012-04-26 2014-08-06 四川大学华西医院 一种可用于麻醉剂的化合物
RU2667010C2 (ru) 2012-08-21 2018-09-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса
EP4335505A3 (de) 2012-11-30 2024-06-05 The Regents of The University of California Antikonvulsive aktivität von steroiden
SI3461834T1 (sl) * 2013-03-13 2021-11-30 Sage Therapeutics, Inc. Nevroaktivni steroidi
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
CA2909546C (en) * 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
EP3868382A1 (de) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroaktive steroide, zusammensetzungen und verwendungen davon
DK3488852T3 (da) 2013-08-23 2021-02-01 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
ES2927007T3 (es) * 2014-05-29 2022-10-31 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP4306114A1 (de) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterole und verfahren zu ihrer verwendung
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3206494A4 (de) * 2014-10-16 2018-07-04 Sage Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
SI3206493T1 (sl) 2014-10-16 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
PL3224269T3 (pl) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PE20180482A1 (es) 2015-07-06 2018-03-07 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3319611T2 (ro) 2015-07-06 2021-06-30 Sage Therapeutics Inc Oxisteroli și metode de utilizare a acestora
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
JP6838074B2 (ja) 2016-03-08 2021-03-03 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
AU2017240157B2 (en) 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3481846T3 (da) 2016-07-07 2021-08-16 Sage Therapeutics Inc 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
EP3529257B1 (de) 2016-10-18 2023-05-10 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
WO2018075698A1 (en) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2019264032A1 (en) * 2018-05-04 2020-12-03 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
ES2966055T3 (es) * 2018-10-12 2024-04-18 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
JP2022516986A (ja) * 2019-01-08 2022-03-03 成都康弘薬業集団股▲フン▼有限公司 ステロイド化合物、その使用、およびその調製方法
CN111410673A (zh) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
JP7340023B2 (ja) * 2019-01-14 2023-09-06 ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド テトラゾロン置換ステロイド及びその使用
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos
CN112638928B (zh) * 2019-08-07 2023-12-22 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
CN112341511A (zh) * 2019-08-09 2021-02-09 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物及其用途
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP2023539125A (ja) * 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274179A (en) * 1964-03-19 1966-09-20 Merck & Co Inc 3-haloethynyl-3-hydroxy derivatives of the androstane-17-one and pregnane-20-one series
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
JPH06510999A (ja) * 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
EP0701444B1 (de) * 1993-05-24 2010-04-07 Purdue Pharma Ltd. Verfahren und zusammensetzungen zum hervorrufen von schlaf

Also Published As

Publication number Publication date
JPH09510701A (ja) 1997-10-28
WO1995021617A1 (en) 1995-08-17
EP1038880B1 (de) 2007-10-17
DK0752860T3 (da) 2000-11-13
KR100338287B1 (ko) 2002-11-30
JP4066272B2 (ja) 2008-03-26
ES2296594T3 (es) 2008-05-01
DE69535623D1 (de) 2007-11-29
NZ282939A (en) 1998-08-26
DK1038880T3 (da) 2008-03-03
ES2151593T3 (es) 2001-01-01
ATE375993T1 (de) 2007-11-15
NO963355D0 (no) 1996-08-12
ATE195654T1 (de) 2000-09-15
DE69535623T2 (de) 2008-07-24
EP0752860A4 (de) 1998-05-06
FI963174A0 (fi) 1996-08-13
EP1038880A3 (de) 2003-07-16
HK1014665A1 (en) 1999-09-30
GR3034810T3 (en) 2001-02-28
NO963355L (no) 1996-10-11
FI20051271A (fi) 2005-12-09
DE69518509D1 (de) 2000-09-28
FI118008B (fi) 2007-05-31
FI118687B (fi) 2008-02-15
CA2183231A1 (en) 1995-08-17
DE69518509T2 (de) 2001-04-19
EP0752860A1 (de) 1997-01-15
AU2090195A (en) 1995-08-29
BR9506779A (pt) 1997-10-14
FI963174A (fi) 1996-09-25
PT752860E (pt) 2000-12-29
EP1038880A2 (de) 2000-09-27
AU691905B2 (en) 1998-05-28
PT1038880E (pt) 2008-01-29
IL112638A0 (en) 1995-05-26
IL112638A (en) 2003-10-31
EP0752860B1 (de) 2000-08-23

Similar Documents

Publication Publication Date Title
NO308307B1 (no) Forbindelse, farmasøytisk preparat omfattende denne samt anvendelse derav
UA48154C2 (uk) СПОЛУКИ РЯДУ АНДРОСТАНІВ ТА ПРЕГНАНІВ ДЛЯ АЛОСТЕРИЧНОЇ МОДУЛЯЦІЇ РЕЦЕПТОРА <font face="Symbol">g</font>-АМІНОМАСЛЯНОЇ КИСЛОТИ
ES2149800T3 (es) Procedimientos enzimaticos para la resolucion de mezclas enantiomericas de compuestos utiles como intermediarios en la preparacion de taxanos.
AR227063A1 (es) Procedimiento para la produccion de nuevos acidos 7-amino-1-ciclopropil-4-oxo-1,4-dihidro-(1,6-y 1,8-naftiridina o quinolina)-3-carboxilicos
NO910187D0 (no) Fremgangsmaate for fremstilling av indolsubstituerte, heteroaromatiske femringforbindelser.
NO902319L (no) Fremgangsmaate for aa bestemme egenskaper vedroerende stroemningsdynamikk for flerfasestroemning.
IT7925382A0 (it) Procedimento per l'analisi di sostanze organiche.
DK0450991T3 (da) Anvendelse af phospholipider til behandling af luftvejsobstruktionssygdomme
ES516556A0 (es) Procedimiento para la obtencion de acidos 1-carboxi-(azaalcanoil o azaaralcanoil)-indolin-2-carboxilicos.
BR8804011A (pt) Metodo para fabricacao de fecho corredico separavel
DK98781A (da) 3,3-dimethyl-1-phenoxybutan-2-oler, fremgangsmaade til deres fremstilling samt deres anvendelse som mellemprodukter
DE69022711D1 (de) Einrichtung zur Regelung der Lichtmenge.
DE69004417D1 (de) Oral verabreichte porphyrine zur regelung der eisenabsorption.
NO863787D0 (no) Anordning for anbringelse av am.baand/kasser ved stativ for tyngre haandvaapen.
AT372943B (de) Verfahren zur herstellung des neuen vitamin d3derivates 1alpha,25,26-trihydroxycholecalciferol
AR229873A1 (es) Procedimiento para la preparacion de nuevos 3-2-hidroxi-fenil-4-sustituido-4 o 5-sustituido cicloalcanoles y derivados de los mismos,utiles como agentes analgesicos y como agentes antiemeticos y compuestos intermedios utilizados
DE68919179D1 (de) Einrichtung zur Regelung der Lichtmenge.
DE3669159D1 (de) Triazinderivate, verfahren zur herstellung dieser derivate und herbizide, welche diese derivate als wirksame komponente enthalten.
DE3688451D1 (de) Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen.
AR228572A1 (es) Procedimiento para la preparacion de compuestos de organoestano,que contienen azufre en su molecula
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose
FI942663A0 (fi) Indexstruktur foer att uppraetthaolla en databas
ES241295Y (es) Pasamuros perfeccionado para la conduccion de fluidos.
ES1024406Y (es) Nueva disposicion para la presentacion de palillos.
FI940088A0 (fi) Regleranordning/reglerdel foer spolvattenmnaengden i en vattenklosett

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees